

Provided by:



Pulmonary and Critical Care Summer Lecture Series 2025-2026

Pulmonary and Critical Care Summer Lecture Series 2025-2026 - 8/18/2025 Clinical Implementation of ARDS Management August 18, 2025 8:00 AM - 9:00 AM

Target Audience

This program has been designed for INTERNAL MEDICINE - Pulmonary Disease, THORACIC AND CARDIAC SURGERY, ANESTHESIOLOGY - Critical Care Medicine, INTERNAL MEDICINE - Critical Care Medicine, SURGERY - Surgical Critical Care

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss how to initiate appropriate mechanical ventilator settings for a patient with acute respiratory failure.
- 2 Describe how to appropriately order and interpret pulmonary function tests for an outpatient.
- 3 Describe an asthmatic patient for level of control and adjust medications accordingly.

Session Educational Objectives

After completing this educational activity, participants should be able to:

- 1 Review different strategies for PEEP selection and titration, and adopt a personalized approach.
- 2 Discuss the data behind corticosteroids in the ARDS and have a rationale to use or decline steroid use.
- 3 Describe areas of uncertainty to personalize ARDS ventilation / meds

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for **1.00** contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

Acknowledgement of Commercial Support*

None

For more information, please contact
Melissa Englehardt, Starr Scorsone
(215) 615-3718, (215) 614-0871
melissa.engagehardt@uphs.upenn.edu, starrsc@upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Caitlin Clancy, MD	Co-Director	Nothing to disclose - 11/18/2024
Maryl E Kreider, MD, MSCE	Course Director	Grant or research support-United Therapeutics (Relationship has ended) Grant or research support-Bristol-Myers Squibb Grant or research support-Pliant Therapeutics Grant or research support-Boehringer-Ingelheim Grant or research support-Bellerophon (Relationship has ended) - 07/07/2025
Nuala J Meyer, MD-FCBC	Faculty	Grant or research support-Athersys, Inc (Relationship has ended) Grant or research support-BioMarck, Inc (Relationship has ended) Grant or research support-Bayer (Relationship has ended) Grant or research support-Quantum Leap Healthcare Colloborative (Relationship has ended) Consulting Fee-Astra Zeneca Pharmaceuticals (Relationship has ended) Consulting Fee-Novartis AMGEN (Relationship has ended) - 07/30/2025
Kathryn Fenwick, CRNP RN	Nurse Planner	Advisor-Boehringer-Ingelheim (Relationship has ended) - 07/07/2025

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment,

management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected